Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* primary single or bilateral lung allograft~* original disease cystic fibrosis, COPD, emphysema, idiopathic pulmonary fibrosis or A1AD~Exclusion Criteria:~* lung allograft retransplantation~* multiple organ transplantation~* severe gastrointestinal disorder~* malignancies or history of malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mycophenolate Mofetil; Cystic Fibrosis (Type: EXPERIMENTAL): Participants with cystic fibrosis will receive mycophenolate mofetil 1.5 g, orally (PO), BID from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.
- Mycophenolate Mofetil; Other (Type: EXPERIMENTAL): Participants with COPD, emphysema, idiopathic pulmonary fibrosis, or A1AD will receive mycophenolate mofetil 1.5 g, PO, BID, from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).